Glofitamab-gxbm: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

23 May 2024

  • curprev 14:5114:51, 23 May 2024Muhammad Waleed talk contribs 8,803 bytes +6,189 No edit summary
  • curprev 14:4014:40, 23 May 2024Muhammad Waleed talk contribs 2,614 bytes +2,614 Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=glofitamab. |aOrAn=a |drugClass=bispecific antibodies |indicationType=treatment |indication=COLUMVI (glofitamab) has been approved by the FDA for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or large B-cell lymphoma arising from follicular lymphoma aft..."